California Policy Recommendations for Realizing the Promise of Medication Abortion: How the COVID-19 Public Health Emergency Offers a Unique Lens for Catalyzing Change by Pinchuk, Kerri
Hastings Race and Poverty Law Journal 
Volume 18 
Number 2 Summer 2021 Article 5 
Summer 2021 
California Policy Recommendations for Realizing the Promise of 
Medication Abortion: How the COVID-19 Public Health Emergency 
Offers a Unique Lens for Catalyzing Change 
Kerri Pinchuk 
Follow this and additional works at: https://repository.uchastings.edu/hastings_race_poverty_law_journal 
 Part of the Law and Race Commons 
Recommended Citation 
Kerri Pinchuk, California Policy Recommendations for Realizing the Promise of Medication Abortion: How 
the COVID-19 Public Health Emergency Offers a Unique Lens for Catalyzing Change, 18 HASTINGS RACE & 
POVERTY L.J. 265 (2021). 
Available at: https://repository.uchastings.edu/hastings_race_poverty_law_journal/vol18/iss2/5 
This Article is brought to you for free and open access by the Law Journals at UC Hastings Scholarship Repository. 
It has been accepted for inclusion in Hastings Race and Poverty Law Journal by an authorized editor of UC 
Hastings Scholarship Repository. For more information, please contact wangangela@uchastings.edu. 
1 - CAPULONG_KING_RIES HRPLJ V18-1 (DO NOT DELETE) 4/7/2021 1:05 AM 
 
[265] 
California Policy Recommendations for 
Realizing the Promise of Medication Abortion: 
How the COVID-19 Public Health Emergency 






Abstract: While the new composition of the United States Supreme Court 
has raised speculation about the fate of Roe v. Wade, for millions in America 
the promise of a patient’s right to choose an abortion is already a distant 
illusion.** Decades of work by anti-abortion policymakers has resulted in 
prohibitive state and federal funding restrictions and widespread clinic 
closures. But clinicians, advocates, and researchers are optimistic about one 
way to expand access: medication abortion. Known colloquially as “the 
abortion pill,” medication abortion is poised to significantly increase access 
for patients everywhere, and particularly for low-income patients and those 
who live in rural areas far from hospitals and clinics.  
 One of the biggest barriers to medication abortion today is a stringent 
set of FDA regulations implemented under the guise of patient safety 
protocols, which evidence suggests are not only medically unnecessary but 
politically motivated. While researchers and advocates have been working to 
lift these restrictions for years, the unprecedented COVID-19 pandemic has 
provided unique circumstances for studying how access would be affected if 
the restrictions were to be permanently lifted.  
 In California, there are three legislative steps that the state can take to 
 
 * Juris Doctor Candidate, University of California, Hastings College of the Law. Thanks 
to Professor Steven Bonorris for his guidance and Jennifer Dunn for her mentorship. Special 
thanks to Lisa Matsubara for her time and critical input. All identifiers used in this note are 
taken directly from their sources (e.g. studies, direct quotes, etc.) and are not the author’s 
preference. 
 ** Many abortion rights advocates believe that the election of pro-choice President Joe 
Biden in November 2020 presents opportunities for codifying protections of a patient’s right 
to choose. Given intense conservative opposition to abortion protections in the current 
Congress, such executive action would undoubtedly give way to legal action. To avoid the 
myriad hypothetical situations that could arise, this note will not address those potential 
avenues and will instead focus on the national legislative and judicial status quo.  
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ensure that Californians have continued access to abortion as guaranteed by 
the State Constitution, and to expand access to low-income patients and 
patients in rural areas. First, the State should support the creation of a 
centralized database for collecting medication abortion data from across the 
state while restrictions were lifted. Second, the State should remove the dual-
ultrasound requirement for Medi-Cal reimbursement. Third, the State should 
close a loophole in current policy that prevents minors from obtaining 
medication abortion via telehealth. 
 It is clear that politicization of reproductive rights will remain a fixture 
of civil discourse in America for years to come. At the same time, advances 
in telehealth technology have already provided a glimpse into a future where 
patients are able to access the reproductive care they need. As a national 
leader in reproductive justice efforts, California has the opportunity to create 
lasting impact by exploring efforts to expand access to key patient 
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I. INTRODUCTION 
 
 Medication abortion (MAB), commonly referred to as the “abortion pill,” 
is a safe and effective method of self-managed abortion.1  MAB has become 
an increasingly popular choice among patients seeking both therapeutic and 
elective abortions.  More than four million women have used MAB to end an 
early pregnancy in the United States.2  Now the most commonly used method 
of abortion for pregnancies up to ten weeks’ gestation, MAB accounted for 
sixty percent of all such abortions in the United States in 2017.3  Patients opt 
for MAB over surgical procedures for a variety of reasons, chief among them 
the privacy, comfort, and convenience of passing a pregnancy at home, which 
often comes with the support of friends or family.  
 In addition to these patient benefits, clinicians, advocates, and experts 
across the country celebrate MAB for its power to expand access to low-
income patients and patients living in rural areas.4  But this power remains 
largely inhibited by federal dispensation requirements, costly components of 
care delivery, low reimbursement rates for providers, and, importantly, 
obstruction by anti-abortion politicians.  Among many other gaps in the U.S. 
health care system, these barriers to MAB provision have been highlighted 
by the COVID-19 public health emergency.  
 MAB involves a pill regimen of two medications, mifepristone (brand 
name Mifeprex) and misoprostol (brand name Cytotec, among others), 
prescribed by a clinician and ingested successively.5  First, mifepristone 
blocks the body’s production of progesterone, the hormone necessary for a 
pregnancy to develop, effectively terminating the pregnancy.6  Taken up to 
forty-eight hours later, misoprostol then causes uterine contractions and 
cervical dilation, ultimately expelling the contents of the uterus.7  Federal law 
requires that the pills be dispensed to patients by a clinician, but depending 
on state laws, ingestion takes place in the presence of the prescribing clinician 
 
 1 Megan Donovan, Medication Abortion and the Changing Abortion Landscape, 
GUTTMACHER INST., https://www.guttmacher.org/article/2019/09/medication-abortion-and-
changing-abortion-landscape (last visited Mar. 8, 2021).  
 2 Extrapolated from the FDA’s “Mifepristone U.S. Post-Marketing Adverse Events 
Summary through 12/31/2018,” which found that 3.7 million women had used mifepristone 
to end a pregnancy in the United States through the end of 2018. Mifepristone U.S. Post-
Marketing Adverse Events Summary through 12/31/2018, FDA, 
https://www.fda.gov/media/112118/download (last visited Mar. 9, 2021).    
 3 Donovan, supra note 1. 
 4 Id. 
 5 The Abortion Pill, PLANNED PARENTHOOD, 
https://www.plannedparenthood.org/learn/abortion/the-abortion-pill (last visited Mar. 13, 
2021). 
 6 Id. 
 7 Id. 
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or at a time and location of the patient’s choosing.8,9  In California, the patient 
may ingest the pills at a time and location of their choice.10  For the purposes 
of this note, I will focus almost exclusively on mifepristone because it is 
heavily restricted by the United States Food and Drug Administration 
(FDA).11  Misoprostol is commonly prescribed for uses other than MAB, 
including inducing labor and ripening the cervix before medical procedures, 
and is thus far less heavily restricted.12  
 The COVID-19 public health emergency has highlighted disparities and 
opportunities for increasing access to MAB in California.  The disparities are 
evident in reduced access for vulnerable patient populations due to increased 
financial hardship and diminished access to care.  The opportunities lie in the 
fact that the temporarily relaxed in-person restrictions for MAB provisions 
created a window for understanding what the future of MAB could look like.  
This note considers the current landscape of MAB and ultimately provides 
three recommendations for actions California can take to ensure maximum 
and continuous access to MAB beyond the COVID-19 public health 
emergency: first, the State should foster collection and analysis of no-touch 
MAB and TeleMAB (MAB prescribed via telehealth) data collected while 
the FDA’s in-person requirements were lifted.13  Second, the State should 
remove the costly dual-ultrasound requirement for Medi-Cal 
reimbursement.14  Third, the State should close a loophole in current 
telehealth policy that would prevent minors from accessing TeleMAB 
services.15  
 This note begins by providing an introduction to the FDA’s restrictions 
of MAB and its arguably politically motivated restrictions at the federal 
level.16  It also traces a brief history of MAB access during the COVID-19 
pandemic, setting the stage for understanding how the temporary removal of 
 
 8 Mifeprex (mifepristone) Information, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-
providers/mifeprex-mifepristone-information (last visited Mar. 8, 2021) [hereinafter FDA, 
Mifepristone Information].  
 9 PLANNED PARENTHOOD, supra note 5; The Availability and Use of Medication Abortion, 
KAISER FAM. FOUND. (June 8, 2020), https://www.kff.org/womens-health-policy/fact-
sheet/the-availability-and-use-of-medication-abortion/.  
 10 State Laws and Policies: Medication Abortion, GUTTMACHER INST. (updated Mar. 1, 
2021), https://www.guttmacher.org/state-policy/explore/medication-abortion (listing states 
that require physicians to administer medication abortion and states that require the clinician 
to be physically present when the medication is administered). 
 11 See FDA, Mifepristone Information, supra note 8. 
 12 Rebecca Allen & Barbara M. O’Brien, Uses of Misoprostol in Obstetrics and 
Gynecology, REV. OBSTETRICS & GYNECOLOGY, Summer 2009, at 159. 
 13 See infra section II.C.  
 14 See infra section III.C. 
 15 See infra section IV.B. 
 16 See infra section II.A. 
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in-person requirements may have affected access for Californians.17  Next, 
this note discusses restrictions on public funding at the federal and state level 
that decrease access for low-income and rural patients—and specifically, 
how the impacts of California’s low reimbursement rates can be mitigated by 
removing the ultrasound requirement for MAB.18  Finally, this note finishes 
by proposing a solution for a loophole currently preventing minors from 
accessing TeleMAB in California.19 
 
II. BACKGROUND: THE FDA’S REGULATION OF 
MIFEPRISTONE AND THE EFFECTS OF COVID-19 
 
A major barrier to MAB access across the country is a set of federal 
restrictions the FDA places on the prescription and dispensation of 
mifepristone.  A true expansion of MAB access necessitates the permanent 
removal of these restrictions.  While many states place additional restrictions 
on MAB, California has few and is thus an ideal setting for understanding 
gaps and opportunities that exist in the push for expanding access.  COVID-
19 catalyzed a chain of events that allows for this analysis. 
 
A. The FDA’s REMS for Mifepristone are Motivated by Politics, 
Not Patient Safety 
 
 As mentioned above, MAB involves a pill regimen of two medications: 
mifepristone and misoprostol, ingested successively.20  This section 
examines each of the Risk Evaluation and Mitigation Strategy (REMS) 
restrictions that the FDA imposes on mifepristone to underscore expert 
assessments that they are not medically necessary.  According to the FDA, 
REMS are designed to help reduce the “occurrence or severity of a particular 
serious adverse event.”21  The below exploration is based largely on the 
substance of plaintiffs’ argument in Chelius v. Azar, an ongoing federal 
lawsuit brought on behalf of a Hawai‘i doctor and several professional health 
care organizations.22  Chelius challenges the constitutionality of the REMS 
as placing significant burdens, with no medical basis, on women seeking 
 
 17 See infra section II.B. 
 18 See infra section III.A-C. 
 19 See infra section IV.A-B. 
 20 PLANNED PARENTHOOD, supra note 5. 
 21 Frequently Asked Questions About REMS, U.S. FOOD & DRUG ADMIN. (Jan. 26, 2018), 
https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/frequently-asked-
questions-faqs-about-rems. 
 22 Complaint at 19, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
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medication abortions.23  The plaintiffs’ case relies heavily on data from the 
FDA’s own 2016 medical review of Mifeprex.24 Abortion advocates hope 
that the outcome of this case will lead to a permanent removal of the REMS 
restrictions.  
 In 2000, the FDA approved Mifeprex for use up to forty-nine days into a 
pregnancy (today it is approved for up to seventy days).25  Despite a 
substantial safety record of data from U.S. trials and European markets, the 
FDA assigned three significant REMS restrictions to the drug as a condition 
of approval: explained in detail below, two restrictions require a patient to 
present in person for prescription and dispensation, and the other requires 
providers to submit specific documentation to the drug manufacturer.26  After 
the FDA determines that a REMS is necessary and specifies the requirements, 
the drug manufacturer is then responsible for developing and implementing 
the program.27  The FDA may later release or lift certain components of a 
REMS if it determines that the extra measures are no longer necessary to 
ensure a medication’s benefits outweigh its risks.28 
 The most burdensome types of REMS are “Elements to Assure Safe Use” 
(ETASU), which the FDA may impose on a drug that has been shown to be 
effective only if it is associated with a “serious adverse drug experience” 
(defined as resulting in death, immediate risk of death, inpatient 
hospitalization, a persistent or significant incapacity or substantial disruption 
of the ability to conduct normal life functions, or a congenital anomaly or 
birth defect).29,30  In 2017, of the nearly 1,800 FDA-approved prescription 
drugs and therapeutic biologic active ingredients on the U.S. market, only 
seventy-three were subject to a REMS—and just forty-three were subject to 
a REMS with ETASU.31  Importantly, ETASU are not to be “unduly 
burdensome on patient access to the drug, considering in particular … 
patients who have difficulty accessing health care (such as patients in rural 
 
 23 Complaint at 19, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). When the 
complaint was filed in 2017, it named then-Acting Secretary of Department of Health and 
Human Services Don Wright. Later stages of litigation name Secretary Alex Azar. Id. 
 24 Id. (citing U.S. FOOD & DRUG ADMIN., CTR. FOR DRUG EVALUATION & RSCH., App. 
No. 020687Orig1s020, Mifeprex Medical Review(s) (Mar. 29, 2016), available at 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020MedR.pdf (last 
visited Mar. 10, 2021)).  
 25 FDA, Mifepristone Information, supra note 8. 
 26 Complaint, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
 27 Id. 
 28 Id. 
 29 Complaint at 18-19, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug 
Admin., 2020 WL 2771735 (D.Md.). 
 30 21 U.S.C.A. § 355-1. 
 31 Complaint at 4, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
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or medically underserved areas).”32  In California, the Medi-Cal Provider 
Manual mandates that providers adhere to the enumerated FDA REMS in 
order to bill for a bundled payment reimbursement for MAB.33  Considering 
that Medi-Cal covers about half of abortions in California, we know that the 
Mifeprex REMS with ETASU directly impact many low-income patients 
across the state.34  California adults qualify for Medi-Cal if their income is 
up to 138% of the federal poverty level, or $17,609 in 2020.35  
 The three ETASU assigned to Mifeprex are as follows: 
• ETASU A: Clinicians prescribing mifepristone must send a 
prescriber agreement form to the drug distributor attesting to 
their clinical abilities, agreeing to comply with certain reporting 
requirements, and agreeing to comply with other REMS 
elements.36  
• ETASU C: Mifepristone may be dispensed only in a hospital, 
clinic, or medical office—not in retail pharmacies—by or under 
the supervision of a certified prescriber.37 
• ETASU D: The prescriber and patient must, in person, review 
and sign a special Patient Agreement Form containing 
information regarding the mifepristone.38 
 According to experts, the FDA’s decision to place these stringent 
regulations on Mifeprex was “highly unusual.”39  Nearly twenty years of data 
provides Mifeprex with a record of up to ninety-nine percent efficacy and 
exceptional safety.40  In the first fifteen years of U.S. post-marketing data on 
Mifeprex, there were seventeen reported associated deaths out of 2.5 million 
uses—an associated fatality rate of 0.00068%.41  Further, in 2016 the FDA 
determined that because adverse events associated with mifepristone are so 
 
 32 21 U.S.C.A. § 355-1. 
 33 Medi-Cal Provider Manual for abortion (abort) at 7, CALIF. DEP’T OF HEALTH CARE 
SERVS. (updated Sept. 16, 2020), available at https://filesaccepttest.medi-
cal.ca.gov/pubsdoco/Publications/masters-MTP/Part2/abort.pdf [hereinafter Medi-Cal 
Provider Manual].  
 34 Nicole E. Johns, Diana Greene Foster & Ushma D. Upadhyay, Distance traveled for 
Medicaid-covered abortion care in California, 17 BMC HEALTH SERV. RES. 287 (2017) (citing 
CALIF. DEP’T OF HEALTH CARE SERVS., Medi-Cal funded induced abortions, 2010). 
 35 Do You Qualify for Medi-Cal Benefits?, CALIF. DEP’T OF HEALTH CARE SERVS. (May 
5, 2020), https://www.dhcs.ca.gov/services/medi-cal/Pages/DoYouQualifyForMedi-Cal.aspx. 
 36 21 U.S.C.A. § 355-1(f)(3)(A). 
 37 21 U.S.C.A. § 355-1(f)(3)(C). 
 38 21 U.S.C.A. § 355-1(f)(3)(D). 
 39 Complaint at 20, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
 40 U.S. FOOD & DRUG ADMIN., CTR. FOR DRUG EVALUATION & RSCH., App. No. 
020687Orig1s020, Mifeprex Medical Review(s) at 23 (Mar. 29, 2016), available at 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020MedR.pdf (last 
visited Mar. 10, 2021) [hereinafter FDA, Mifeprex Medical Review]. 
 41 Id. at 82-83. 
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rare, it was appropriate for the manufacturer to cease reporting adverse events 
other than death.42  The FDA has acknowledged that “[t]here is no 
information that use of Mifeprex and misoprostol caused the ‘very small 
number’ of deaths from infection. Rather… [CDC findings suggest] 
pregnancy itself was the ‘critical risk factor’ [in] cases of fatal infection.”43  
Ironically, given the United States’ dismal maternal mortality rate, the 
associated fatality risk of carrying a pregnancy to term is about fourteen times 
greater than the risk of using Mifeprex.44  
 By way of comparison, mifepristone-based drug Korlym is often 
prescribed as treatment for Cushing syndrome, a disease caused by high 
levels of the hormone cortisol.45,46  Even though Korlym is taken daily, at 
home, in higher doses, and with higher rates of adverse events than Mifeprex, 
Korlym is not subject to a REMS.47  In a final comparison, the fatality rate 
associated with phosphodiesterase type five inhibitors for the treatment of 
erectile dysfunction (e.g., Viagra) is estimated at 0.0026%, roughly four 
times that of Mifeprex.48  Yet, prescription Viagra is not subject to a REMS.49  
These statistics, considered in light of brazen and persistent calls by anti-
abortion politicians to ban MAB specifically, suggest that the REMS are 
motivated not by concern for patient safety but by political will.50 
 Provider certification like the kind required by ETASU A is not required 
for professionals to dispense many other drugs, some of which include “black 
box” warnings about their risks.51  Moreover, the prescriber agreement forces 
abortion providers to self-identify to an entity that is routinely inspected by 
 
 42 Complaint at 35, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
 43 Id. at 38. Of the seventeen reported deaths in women who had taken Mifeprex, five 
involved events unrelated to the medication, such as narcotic overdose or suspected homicide. 
Id. 
 44 Id. at 3. 
 45 FDA, Mifeprex Medical Review, supra note 40, at 10. 
 46 “Cushing syndrome occurs when [a] body is exposed to high levels of the hormone 
cortisol for a long time.”  Cushing Syndrome, MAYO CLINIC, 
https://www.mayoclinic.org/diseases-conditions/cushing-syndrome/symptoms-causes/syc-
20351310. 
 47 FDA, Mifeprex Medical Review, supra note 40, at 10. 
 48 Complaint at 38, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).  
 49 Id. at 35. 
 50 William Cummings, 'Pregnancy is not a life-threatening illness': Ted Cruz takes heat 
in call to ban abortion pill, USA TODAY (Sept. 3, 2020), 
https://www.usatoday.com/story/news/politics/2020/09/03/ted-cruz-pregnancy-not-life-
threatening-abortion-bill-ban/5700978002/. 
 51 A “black box warning” or “boxed warning” appears on a prescription drug’s label and 
is designed to call attention to serious or life-threatening risks.  Consumer Health Information, 
A Guide to Drug Safety Terms at FDA at 2, U.S. FOOD & DRUG ADMIN. (Nov. 2012), 
https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf. 
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the federal government.52  Considering some policymakers’ politicization of 
abortion rights and the violence routinely perpetrated against abortion 
providers, this requirement effectively weeds out clinicians who may be 
uncomfortable publicly identifying as abortion providers—especially in 
abortion-hostile regions.53  With fewer providers willing to stock the 
medication, there are fewer opportunities for patients to access MAB in 
places where state-level restrictions already pose significant barriers. 
 Particularly resonant for the goals of this note, the in-person dispensation 
requirement (ETASU C) serves no medical purpose.  Of the three ETASU 
assigned to Mifeprex, this requirement is among the rarer ETASU assigned 
to a drug and provides the biggest barrier to access for patients.  Out of more 
than 20,000 drugs regulated by the FDA—including self-administered 
injectables, opioids, and other drugs with high potential for danger or 
abuse— Mifeprex is the only one that patients must receive in person at a 
hospital, clinic, or medical office, yet may self-administer unsupervised at a 
location of their choice.54  Experts agree that the dispensing location has no 
effect on the safety or efficacy of the medication.55  As the Mifeprex label 
makes clear, the medication’s effects do not begin until hours after ingestion: 
“most women will expel the pregnancy within 2 to 24 hours of taking 
misoprostol [the second drug in the regimen].”56  This amounts to a total of 
twenty-six to seventy-two hours after taking mifepristone; and for patients in 
states with mandatory waiting periods for abortion care, this could mean up 
to four days after the patient first presents to a clinician.  It is highly unlikely 
that a patient will still be under the direct supervision of her certified 
prescriber if she experiences adverse effects at that time.  In short, “there is 
no relationship between where a woman is standing when she receives the 
Mifeprex pill and any potential risk of infection or bleeding.”57  There is no 
 
 52 Complaint at 27, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i) (citing to Letter 
from SFP, et al., to Stephen Ostroff, M.D., Robert M. Califf, M.D., & Janet Woodcock, M.D. 
(Feb. 4, 2016)). 
 53 Id.  In 2014, one in five U.S. health care facilities that provide abortions experienced 
“severe violence” such as blockades, invasions, bombings, arsons, chemical attacks, physical 
violence, stalking, gunfire, bomb threats, arson threats, or death threats.  
 54 Complaint at 3, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug 
Admin., 2020 WL 2771735 (D.Md.). 
 55 Complaint at 41, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
 56 Mifeprex (Mifepristone) Tablets Label, available at 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf (last visited 
Mar. 13, 2021). Mifeprex labeling is a rigorous part of the FDA approval process. Thanks to 
persuasion from doctors and professional medical associations—including some plaintiffs in 
the Chelius case—the FDA has made significant updates to the Mifeprex label over time that 
more accurately communicate its uses. 
 57 Complaint at 37, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
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evidence-based connection between in-person dispensation and patient 
safety. 
 Similarly, regarding ETASU D, there is no data suggesting that a 
patient’s location when signing a form has any effect on the safety or efficacy 
of the medication—whether she is signing it in the physical presence of a 
doctor or virtually via a telehealth visit.  But more importantly, many 
clinicians agree that the signing of the Patient Agreement form is altogether 
duplicative, emotionally draining, and interferes with the patient-physician 
relationship.58  Abortion patients already receive extensive counseling under 
standard informed consent practices, they receive the FDA-regulated 
Medication Guide for Mifeprex, and they are subject to additional counseling 
practices that vary across states and individual clinics or hospitals.59  Adding 
an additional layer of consultation via a Patient Agreement form is, again, 
not medically necessary.  
 Finally, as with any substance regulated by the government, erecting 
barriers to access cements the risk of desperate patients turning to sketchy 
sources.  While more research is needed to understand the scope of this issue, 
we know that some patients obtain MAB drugs online from unlicensed 
foreign sellers.60  These patients have no clinical supervision, have not 
undergone a professional screening, and may not understand potential 
contraindications resulting in true adverse reactions.  These conditions set a 
dangerous stage reminiscent of pre-Roe America, when desperate patients 
resorting to unsafe methods of abortion resulted in an estimated 200 deaths 
per year.61   
 Physicians and experts across the country, including at least one former 
FDA administrator, agree that the outdated REMS should be lifted.62  The 
American College of Obstetrics and Gynecologists (ACOG), the country’s 
leading group of physicians providing health care for women, has urged 
removal of the REMS on behalf of its 60,000 members.63  As of the time of 
 
 58 Telephone Interview with Mary Fjerstad, Clinician, on Nov. 11, 2020 (on file with 
author). 
 59 Complaint at 28-30, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). 
 60 Gabriella Borter, U.S. states unsure how to halt online sales of abortion pills amid 
clinic crackdown, REUTERS (June 27, 2019), https://www.reuters.com/article/us-usa-abortion-
pills/u-s-states-unsure-how-to-halt-online-sales-of-abortion-pills-amid-clinic-crackdown-
idUSKCN1TS1AB. 
 61 All Things Considered: What Abortion Was Like In The U.S. Before Roe v. Wade at 
1:46, NPR (May 20, 2019), https://www.npr.org/2019/05/20/725139713/what-abortion-was-
like-in-the-u-s-before-roe-v-wade.  
 62 Jane E. Henney & Helene D. Gayle, Time to Reevaluate U.S. Mifepristone Restrictions, 
381 THE NEW ENGLAND J. OF MED. 597, 597-98 (2019). 
 63 Improving Access to Mifepristone for Reproductive Health Indications: Position 
Statement, AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS (June 2018), 
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this writing, the Biden-Harris Administration has signaled strong support for 
reproductive rights expansion; however, the president has yet to nominate the 
FDA commissioner who would ultimately make the call to remove the REMS 
on mifepristone.64  A permanent removal of the REMS would not only reduce 
barriers to access, but in some places would allow for completely remote 
provision of TeleMAB.  This is because while eighteen states explicitly 
prohibit abortion via telehealth, other states, including California, have no 
such restrictions.65  While TeleMAB is still in early days of study, researchers 
and advocates feel confident in its promise to substantially reduce costs while 
vastly increasing access.  TeleMAB could remove many of the associated 
costs, stressors, and inconveniences experienced by low-income and rural 
abortion patients, such as traveling to a clinic, taking time off work, securing 
childcare, and undergoing anesthesia.66   
 
B. The COVID-19 Public Health Emergency and MAB 
 
 When the seriousness of the COVID-19 pandemic became evident to the 
public in early 2020, the federal government and all fifty states declared some 
level of public health emergency.67  As travel restrictions, social distancing 
protocols, and decreased capacity at hospitals and clinics vastly hindered 
health care delivery, an obvious means of expanding access to care was 
through telehealth.  Even as the Trump Administration downplayed the 
seriousness of the pandemic, the Department of Health and Human Services 




 64 See Sarah McCammon, Biden Administration Prepares To Overturn Trump Abortion 
Rule, NPR (Jan. 21, 2021), https://www.npr.org/sections/president-biden-takes-
office/2021/01/21/959170860/biden-administration-prepares-to-overturn-trump-abortion-
rule; Laurie McGinley, Biden’s delay on naming FDA chief perturbs some experts, WASH. 
POST (Feb. 11, 2021), https://www.washingtonpost.com/health/2021/02/11/biden-fda-
appointment-covid/. 
 65 Melissa Jeltsen, Coronavirus Is Endangering Abortion Access. Telemedicine Could 
Solve it., HUFF. POST (Mar. 20, 2020), https://www.huffpost.com/entry/medication-abortion-
telemedicine_n_5e74ec23c5b6eab779472982. 
 66 See generally TelAbortion.org, GYNUITY HEALTH PROJECTS, https://telabortion.org/ 
(last visited Mar. 13, 2021). 
 67 Status of State COVID-19 Emergency Orders, NAT’L GOVERNORS ASS’N 
https://www.nga.org/state-covid-19-emergency-orders/ (visited Jan. 23, 2021); Samuel 
Wonacott, All 50 states have active declared emergencies related to the coronavirus 
pandemic, BALLOTPEDIA NEWS (July 29, 2020, 3:47 PM), 
https://news.ballotpedia.org/2020/07/29/all-50-states-have-active-declared-emergencies-
related-to-the-coronavirus-pandemic/. 
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laws.68  In an effort to encourage the use of telehealth services, on April 3, 
2020, California Governor Gavin Newsom issued an executive order 
removing several obstacles to telehealth provision, including the relaxing of 
requirements around signing telehealth consent forms.69 
 Meanwhile, clinicians and advocates witnessed growing challenges for 
those seeking health care across the board: local lockdown mandates 
compounded traditional barriers like financial strain and finding childcare; 
showing up to facilities for in-person care exacerbated the risk of COVID-19 
exposure; and, health risks associated with delays in care grew more dire by 
the day.  Even as at least eleven states seized the opportunity to put more 
restrictions on abortion or ban it outright, advocates took critical steps to 
ensure that abortion care would remain safe and accessible.70  In March 2020, 
ACOG issued a statement acknowledging that dating a pregnancy based on 
a patient’s last menstrual period (LMP) without ultrasound was acceptable 
for MAB.71  In April 2020, leading physicians, researchers, and professional 
organizations developed a “no-touch” or “no-test” protocol deemed not only 
acceptable for MAB provision, but safe, effective, and commensurate with 
the traditional standard of care.72  
 In May 2020, the American Civil Liberties Union (ACLU) filed suit on 
behalf of ACOG to lift the FDA’s REMS requirements on mifepristone.73  
Specifically, the ACLU alleged that the FDA’s continued enforcement of the 
requirements to pick up the medication and sign specific forms in person 
unnecessarily exposed patients and clinicians to heightened risk of exposure 
to COVID-19 for no medical purpose, and that the in-person requirements 
put their health and lives at risk.74  The plaintiffs also pointed out that the 
FDA relaxed in-person requirements for other highly regulated drugs during 
the pandemic, “to afford clinicians discretion to provide appropriate medical 
 
 68 Secretary Azar Announces Historic Expansion of Telehealth Access to Combat 
COVID-19, U.S. DEP’T OF HEALTH & HUMAN SERVS. (Mar. 17, 2020), 
https://www.hhs.gov/about/news/2020/03/17/secretary-azar-announces-historic-expansion-
of-telehealth-access-to-combat-covid-19.html. 
 69 Calif. Exec. Order No. N-43-20 (Apr. 3, 2020), https://www.gov.ca.gov/wp-
content/uploads/2020/04/4.3.20-EO- N-43-20-text.pdf. 
 70 These bans did not survive legal challenges but created confusion and fear among 
patients. 
 71 COVID-19 FAQs for Obstetrician–Gynecologists, Gynecology, AM. COLL. OF 
OBSTETRICIANS & GYNECOLOGISTS, https://www.acog.org/clinical-information/physician-
faqs/covid19-faqs-for-ob-gyns-gynecology (last visited Mar. 13, 2021). 
 72 Elizabeth G. Raymond et al., Commentary: No-test medication abortion: A sample 
protocol for increasing access during a pandemic and beyond, 101 CONTRACEPTION 361, 361-
66 (2020). 
 73 Complaint, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug Admin., 
472 F.Supp.3d 183 (D.Md. 2020), No. TDC-20-1320, 2020 WL 2771735. 
 74 Id. at 18-19. 
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care under these emergency circumstances,” but not mifepristone.75  In a July 
2020 decision, the U.S. District Court for the District of Maryland ruled for 
ACOG in American College of Obstetricians and Gynecologists v. FDA, 
representing a huge win for access.76  The court enjoined the FDA’s in-person 
requirements for prescribing mifepristone for the duration of the public health 
emergency.77  
 The federal injunction immediately impacted MAB provision across the 
country in critical ways.  Most importantly, the injunction allowed 
mifepristone to be dispensed by mail or delivery service unless otherwise 
restricted by state law.78  Though mifepristone still had to be prescribed by 
or under the supervision of a certified health care provider as defined in the 
REMS, mail-order pharmacies could serve as intermediaries, sparing patients 
the in-person trips to their prescribing health care facility.79  Additionally, 
patients were permitted to physically or electronically sign the Patient 
Agreement form during a telehealth appointment and return the form 
electronically or by mail; alternatively, a patient could give verbal consent to 
the terms of the form during a telehealth session.80  The injunction was set to 
apply for thirty days past the end of the national public health emergency.81  
 If there is a silver lining to the COVID-19 pandemic, it is that under the 
injunction providers, researchers, and activists were able to administer MAB 
with significant barriers removed.  But this small win was short-lived.  After 
multiple unsuccessful attempts to stay the injunction, the Trump 
Administration finally prevailed in a last-ditch appeal: on January 12, 2021, 
in its first abortion-related decision since Justice Amy Coney-Barrett’s 
confirmation, the United States Supreme Court re-imposed the in-person 
dispensation and signature requirements.82  In a short concurrence, Chief 
Justice John Roberts opined that the courts should defer to “politically 
accountable entities” on decisions related to pandemic governance.83  In a 
sharp dissent rebuking the Court’s decision, Justice Sonia Sotomayor pointed 
out that a stay of a district court’s injunction has in the past been viewed as 
 
 75 Complaint at 27, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug 
Admin., 472 F.Supp.3d 183 (D.Md. 2020), No. TDC-20-1320, 2020 WL 2771735. 
  76 Order Clarifying July 13 Memorandum Opinion, Am. Coll. of Obstetricians & 
Gynecologists v. U.S. Food & Drug Admin., No. TDC-20-1320, 2020 WL 8167535 (D. Md. 
Aug. 19, 2020). 
 77 Id. 
 78 Id. 
 79 Id. 
 80 Id. 
 81 Id. 
 82 Food & Drug Admin. v. Am. Coll. of Obstetricians & Gynecologists, 141 S. Ct. 578 
(2021). 
 83 Id. at 579. 
3- PINCHUK- HRPLJ V18-2 (DO NOT DELETE) 4/7/2021  1:05 AM 
Summer 2021    CAL. POL’Y RECOMMENDATIONS FOR MEDICATION ABORTION  279 
“extraordinary” relief.84  In addition to highlighting the fact that the pandemic 
has only worsened in the months since the injunction was first ordered, 
Justice Sotomayor called out the FDA’s inconsistent and flawed approach to 
decision-making during the pandemic: “Government policy now permits 
patients to receive prescriptions for powerful opioids without leaving home, 
yet still requires women to travel to a doctor’s office to pick up mifepristone, 
only to turn around, go home, and ingest it without supervision.”85  Abortion 
advocates, including ACOG, have also derided the Court’s decision.86  
 What happens next?  Several advocacy organizations are urging the 
Biden Administration to suspend enforcement of the in-person requirements 
for the duration of the pandemic.87  This would effectively reverse course on 
the Supreme Court’s decision.  In California, a suspension of enforcement 
would allow patients to continue to access MAB via telehealth and mail-order 
pharmacy.  
 
C. Recommendation: California Should Foster Analysis of MAB 
Data Collected While In-Person Requirements Were Lifted 
 
 For the brief period of July through December 2020, TeleMAB was a 
reality for patients across California.  Though it is still too soon to know how 
many patients utilized these services, it is possible that there is significant 
data to inform the State’s planning for MAB expansion, especially if the 
REMS are permanently lifted.  But regardless of the Administration’s 
actions, many advocates feel as though “the cat is out of the bag” and that 
TeleMAB will only continue to expand.88  In preparation for that reality, the 
State of California has a unique opportunity to understand outcomes 
associated with no-touch MAB and TeleMAB: the State should launch an 
effort to centralize and analyze data surrounding MAB provision while the 
REMS were lifted.  
 This would ideally be a repository where providers can share 
comprehensive notes and data – clinic information (including geography and 
 
 84 Am. Coll. of Obstetricians & Gynecologists, 141 S. Ct. at 579 (Sotomayor, J., 
dissenting). 
 85 Id. 
 86 See, e.g., ACOG Action (@ACOGAction), TWITTER (Jan. 12, 2021, 5:16 PM), 
https://twitter.com/ACOGAction/status/1349148168877969411?s=20.  
 87 Georgeanne M. Usova, The Supreme Court Let the Trump Administration Endanger 
Abortion Patients During a Pandemic. The Biden-Harris Administration Can Fix It Right 
Away., ACLU (Jan. 14, 2021), https://www.aclu.org/news/reproductive-freedom/the-
supreme-court-let-the-trump-administration-endanger-abortion-patients-during-a-pandemic-
the-biden-harris-administration-can-fix-it-right-away/. 
 88 Susan Rinkunas, A Bitter Pill, MARIE CLAIRE (Jan. 13, 2021), 
https://www.marieclaire.com/politics/a35203155/pandemic-abortion-telemedicine. 
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community demographics), patient demographics (age, race, income level, 
language preferences), insurance information (particularly around Medi-Cal 
reimbursement), health and safety outcomes, follow-up information, 
anecdotal evidence, testimonials from patients and providers, challenges and 
successes with different technology platforms, experiences with mail-order 
infrastructure, and more. Several private and non-profit entities already 
collect such data points, but there is no centralized effort across the state to 
focus explicitly on COVID-19-era outcomes.89  After collection, the State can 
assess the data and evaluate TeleMAB models based on specific factors such 
as:90  
• Accessibility of services and appointments relative to patient needs 
• Ready supply of MAB relative to patient needs 
• Use of technology platforms and accommodations made for patients 
with disabilities, unstable internet connections, and limited devices 
• Affordability of services 
• Provider comfort level and satisfaction with remote counseling, 
prescription, and dispensation of MAB 
• Patient comfort level and satisfaction with remote counseling, 
prescription, dispensation, and abortion procedure 
• Medical outcomes and adverse drug experiences 
 This information, combined with data from the Department of Health 
Care Services (DHCS) around changes in Medi-Cal reimbursements 
discussed in the next section of this note, will empower California to 
contribute to ongoing research on the promise of TeleMAB—with special 
attention to low-income patients.  After analysis, the State can share its 
findings with those working to expand access at the federal and state levels, 
bolstering the case for permanently removing the REMS restrictions and 
building policy infrastructure for widely accessible TeleMAB. Months’ 
worth of insight can inform policy, guide providers and pharmacies, and 
codify processes for a smooth transition into the future of reproductive health 
care. 
 Opponents would argue that the State has competing priorities during the 
COVID-19 public health emergency, and that California has limited 
resources to direct at a time when the health and economic livelihoods of its 
residents are at stake.  This is a valid argument: data shows that California 
 
 89 Some of these institutions are cited in this note, including Planned Parenthood, Kaiser 
Family Foundation, Ibis Reproductive Health, Guttmacher Institute, and Gynuity Health 
Projects, in addition to researchers at various academic research centers like the University of 
California, San Francisco’s Bixby Center for Global Reproductive Health. 
 90 Telehealth for Medication Abortion Delivery Models, IBIS REPRODUCTIVE HEALTH 
(Oct. 2019) (these criteria suggestions are based off criteria developed by Ibis Reproductive 
Health’s study of telehealth abortion models). 
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experienced massive spikes in infections and death from COVID-19—not to 
mention the devastating impacts to its economy and the health and safety of 
our most vulnerable residents.91  The death rate for Latino people is twenty-
one percent higher than the statewide average; the death rate for Black people 
is six percent higher than statewide; the case rate for Pacific Islanders is 
thirty-one percent higher than statewide; and the case rate for communities 
with median income under $40,000 is thirty-eight percent higher than 
statewide.92  A feasible alternative solution would be for the state to outsource 
or corral organizations across the state that already collect similar data.  This 
solution would involve the aggregation and streamlining of that information 
at the tail end of data collection.  In 2016, nonprofit organization Gynuity 
Health Projects launched a study on TeleMAB with the goal of proving its 
safety and efficacy.93  Now running in thirteen states and the District of 
Columbia, the study tracks pregnant patients who receive virtual counseling 
with an abortion provider, go to any local facility to undergo any necessary 
testing, and then receive mifepristone and misoprostol by mail.94  The State 
could cut down on resource expenses by contracting with an organization like 
Gynuity, which receives funding from a combination of research institutions, 
foundations, and agencies.95  
 A likely obstacle to implementation would be hesitancy on the part of 
providers to submit information about abortion provision.  As previously 
discussed, given the political nature of abortion and the prevalence of anti-
abortion violence, providers are often wary of submitting any identifying 
information about themselves, their patients, and their practices, due to 
privacy, confidentiality, and security concerns.96  One solution to mitigate 
these concerns might be for the State to engage trusted, credible, and 
respected physicians and experts to encourage provider participation.  The 
reproductive rights advocacy community in California is strong and tight-
knit; it is plausible that having a few key people on board early in the process 
may create momentum for participation.  Such a data collection program 
 
 91 Tracking COVID-19 in California, CA.GOV, https://covid19.ca.gov/state-dashboard/ 
(last visited Mar. 13, 2021). At the time of this writing, California has 3,523,563 confirmed 
cases of COVID-19, resulting in 55,095 deaths.  
 92 California’s Commitment to Health Equity, CA.GOV, https://covid19.ca.gov/equity/ 
(last visited Mar. 16, 2021). 
 93 See For Providers & Allies, GYNUITY HEALTH PROJECTS, 
https://telabortion.org/about/for-providers (last visited Mar. 13, 2021). 
 94 TelAbortion, GYNUITY HEALTH PROJECTS, https://telabortion.org/_/assets/TelAbortion-
One-pager-May-2020.pdf (last visited Mar. 13, 2021). 
 95 Donors, GYNUITY HEALTH PROJECTS, https://gynuity.org/donors (last visited Mar. 13, 
2021). 
 96 Telephone Interview with Lisa Matsubara, General Counsel and Vice President of 
Policy, Planned Parenthood Affiliates of California, on Nov. 25, 2020 (on file with author). 
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would necessitate the strictest security, and all identifying information about 
providers and patients would be stripped upon submission. 
 
III. INCREASING MEDICATION ABORTION ACCESS 
UNDER MEDI-CAL 
 
 Public funding represents a significant obstacle for people seeking health 
care across the country.  This is especially true for abortion care, even in 
California.  Despite the State’s express commitment to reproductive rights,97 
current requirements for Medi-Cal reimbursement can make MAB 
inaccessible.  This section discusses funding restrictions, how Medi-Cal 
patients are affected, and why lifting the dual-ultrasound requirement is a 
viable solution.  
  
A. Federal Abortion Funding Restrictions  
 
 A patient’s right to obtain any method of abortion in the United States is 
famously protected by the U.S. Constitution’s Fourteenth Amendment under 
Roe v. Wade.98  But for millions of people of reproductive age across the 
country, access to abortion is difficult.  For low-income patients, patients in 
abortion-hostile states, and patients in rural areas in particular, accessing 
abortion care poses significant challenges.99  This is largely due to gaps in 
funding and relentless efforts by state legislators to shut down abortion 
clinics.  As of March 2020, there were twenty-seven “abortion deserts” in the 
United States, defined as regions where women have to travel more than 100 
miles to access an abortion.100  Six states are down to just one clinic.101  
Depending on location, gestation, and method, early-term abortion services 
range in cost from $300 to about $1,700 and between $300 and $800 for 
MAB.102,103  This does not include associated costs of transportation, missed 
work wages, childcare, and lodging for patients who are forced to travel far 
 
 97 E.g., California Proclamation on Reproductive Freedom (May 31, 2019), available at 
https://www.gov.ca.gov/wp-content/uploads/2019/05/Proclamation-on-Reproductive-
Freedom.pdf. 
 98 Roe v. Wade, 410 U.S. 113 (1973).  
 99 Although Many U.S. Women of Reproductive Age Live Close to an Abortion Clinic, A 
Substantial Minority Would Need to Travel Far to Access Services, GUTTMACHER INST. (Oct. 
3, 2017), https://www.guttmacher.org/news-release/2017/although-many-us-women-
reproductive-age-live-close-abortion-clinic-substantial. 
 100 Jeltsen, supra note 65. 
 101 Id.  
 102 Charlotte Cowles, How Much Does an Abortion Cost? Learn the Facts., THE CUT 
(Nov. 20, 2018), https://www.thecut.com/2018/11/how-much-does-an-abortion-cost.html. 
 103 How Much Does the Abortion Pill Cost?, CARAFEM, https://carafem.org/how-much-
does-the-abortion-pill-cost/ (last visited Feb. 27, 2021). 
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distances to clinics and must observe state-imposed waiting periods between 
counseling and procedure.104  
 Just three years after the Roe decision enshrined the Constitutional right 
to choose an abortion, Congress enacted the Hyde Amendment—a major 
financial barrier to accessing abortion care.105  The Hyde Amendment bans 
federal Medicaid funding for abortion services, except in cases where 
continuing the pregnancy will endanger the life of the patient or when the 
pregnancy results from rape or incest.106  It also restricts abortion funding 
under the Indian Health Service, Medicare, and the Children’s Health 
Insurance Program (CHIP).107  An estimated nineteen percent of women of 
reproductive age in the United States rely on Medicaid.108  The Hyde 
Amendment ensures that those patients pay out-of-pocket for abortion care.  
The policy has withstood legal challenges, most famously in the 1980 case 
of Harris v. McRae, which holds that states are not obligated to pay for 
abortion care and that Hyde does not violate the Fifth Amendment nor the 
Establishment Clause of the First Amendment.109  Though President Biden 
has voiced support for ending the Hyde Amendment, its future remains 
unclear as a majority of Congressional Republicans continue to embrace the 
restriction.110 
 A 2019 regulation promulgated by the Department of Health and Human 
Services represents a more recent effort to limit federal funding for 
abortion.111  Known among abortion care advocates as the “domestic gag 
rule,” the rule effectively forces programs that rely largely on federal Title X 
funding to choose between receiving funds and providing abortion 
services.112  Consequently, many programs, including Planned Parenthood—
 
 104 Cowles, supra note 102; State Laws and Policies: Counseling and Waiting Periods 
for Abortion, GUTTMACHER INST. (updated Mar. 1, 2021), https://www.guttmacher.org/state-
policy/explore/counseling-and-waiting-periods-abortion. 
 105 See Alina Salganicoff, Laurie Sobel & Amrutha Ramaswamy, The Hyde Amendment 
and Coverage for Abortion Services, KAISER FAM. FOUND. (Jan. 2020), 
http://files.kff.org/attachment/Issue-Brief-The-Hyde-Amendment-and-Coverage-for-
Abortion-Services; Hyde Amendment, Pub. L. No. 94-439 § 209, 90 Stat. 1418, 1434 (1976).  
 106 Id. 
 107 Id. 
 108 Id. at 2-3.  
 109 Harris v. McRae, 448 U.S. 297, 326 (1980). 
 110 Juliegrace Brufke, House Republicans vow not to support spending bills that repeal 
Hyde Amendment, THE HILL (Jan. 26, 2021, 11:26 AM), 
https://thehill.com/homenews/house/535863-house-republicans-vow-not-to-support-
spending-bills-that-repeal-hyde-amendment. 
 111 Ruth Dawson, Trump Administration’s Domestic Gag Rule Has Slashed the Title X 
Network’s Capacity by Half, GUTTMACHER INST. (Feb. 5, 2020), 
https://www.guttmacher.org/article/2020/02/trump-administrations-domestic-gag-rule-has-
slashed-title-x-networks-capacity-half. 
 112 Id.  
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the largest network of family planning provision for low-income people in 
country—have withdrawn from the Title X program altogether.113  Before the 
domestic gag rule was instated, around 4,000 clinics received Title X 
funding, serving approximately four million patients annually.114  It is 
estimated that the rule has reduced the Title X network’s capacity by forty-
six percent nationwide, and by much more in many states.115  California is 
one of nine states in which Planned Parenthood served at least fifty percent 
of contraceptive clients served at Title X–funded centers before the rule was 
implemented.116 
 Within days of his inauguration, President Biden took steps to  
“undo the damage” of these Trump Administration policies.117  Most notably, 
the president signed an executive order rescinding the harmful global gag 
rule, which prevented U.S.-funded organizations overseas from providing or 
counseling for abortion services.118  During his campaign, the president 
vowed to similarly reverse the domestic gag rule; as of the time of this 
writing, the Administration has taken steps to “consider” revocation but the 
rule is still in effect.119   
 
B. The Myth of California as a Haven State 
 
 California affords greater protection of a patient’s right to choose an 
abortion than does the U.S. Constitution.  In 1969, California recognized the 
right of procreative choice under the State Constitution.120  In 1972, 
Californians amended the State Constitution to include an explicit protection 
for privacy, which has been interpreted as protecting the right to choose 
 
 113 David Crary & Ricardo Alonso-Zaldivar, Planned Parenthood leaves federal family 
planning program, ASSOCIATED PRESS (Aug. 19, 2019), 
https://apnews.com/article/9e62021bcde04e69aa2ffc2e70a60f8f; see also The Irreplaceable 
Role of Planned Parenthood Health Centers, PLANNED PARENTHOOD (Jan. 2019), 
https://www.plannedparenthood.org/uploads/filer_public/33/63/3363814b-938e-4ad5-87d2-
57ee98790766/190117-irreplaceable-role-pp-v01.pdf. 
 114 Dawson, supra note 111. 
 115 Id. 
 116 The State of California failed in its effort to enjoin the rule in California ex. rel. 
Becerra v. Azar, 950 F.3d 1067 (9th Cir. 2020). 
 117 Ema O’Connor, Biden Just Repealed One of Trump’s Major Anti-Abortion Policies, 
BUZZFEED NEWS (Jan. 28, 2021), https://www.buzzfeednews.com/article/emaoconnor/biden-
executive-order-abortion-global-gag-rule-trump. 
 118 Id. 
 119 Id. 
 120 People v. Belous, 458 P.2d 194, 199 (Cal. 1969) (“[t]he fundamental right of the 
woman to choose whether to bear children follows from the Supreme Court’s and this court’s 
repeated acknowledgement of a ‘right of privacy’ or ‘liberty’ in matters related to marriage, 
family, and sex.”). 
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abortion.121  In 2002, the State legislature codified a statute guaranteeing that 
“every woman has the fundamental right to choose to bear a child or to 
choose and to obtain an abortion.”122  And in 2019, Governor Newsom issued 
an executive “Proclamation on Reproductive Freedom”—a symbolic 
commitment to the recognition and expansion of reproductive rights 
including abortion.123  California is one of sixteen states to use its own 
Medicaid dollars to cover abortion for low-income women for any reason.124  
In addition, the State’s Family Planning Access Care Treatment (PACT) 
program provides coverage for family planning services to uninsured women 
up to two-hundred percent of the federal poverty level.125  All told, an 
estimated twenty-six percent of California women of reproductive age rely 
on Medicaid, and Medi-Cal covers about half of California abortions.126,127  
 This supportive policy environment, plus a massive expansion of Medi-
Cal under the Affordable Care Act, gives California the reputation of a haven 
state for abortion provision.  But the State is not immune to disparities in 
access, particularly when it comes to low-income patients.  The combination 
of a limited number of providers in rural areas, barriers to patient enrollment, 
and low Medi-Cal reimbursement rates significantly deter Medi-Cal-eligible 
abortion patients from getting care.  About forty percent of counties in 
California do not have an abortion provider, and a 2011 study of low-income 
women relying on Medicaid found that twelve percent traveled fifty-plus 
 
 121 CAL. CONST. art. I, § 1; Comm. to Defend Reproductive Rights v. Myers, 625 P.2d 
779, 798 (Cal. 1981). 
 122  CAL. HEALTH & SAFETY CODE § 123462. 
 123 California Proclamation on Reproductive Freedom (May 31, 2019), available at 
https://www.gov.ca.gov/wp-content/uploads/2019/05/Proclamation-on-Reproductive-
Freedom.pdf. 
 124 Alina Salganicoff, Laurie Sobel & Amrutha Ramaswamy, Coverage for Abortion 
Services in Medicaid, Marketplace Plans and Private Plans, KAISER FAM. FOUND. (June 24, 
2019), https://www.kff.org/womens-health-policy/issue-brief/coverage-for-abortion-
services-in-medicaid-marketplace-plans-and-private-plans/ [hereinafter KAISER, Coverage]; 
State Funding of Abortion Under Medicaid, GUTTMACHER INST. (Feb. 1, 2021), 
https://www.guttmacher.org/state-policy/explore/state-funding-abortion-under-medicaid. 
 125 Family PACT, however, does not cover abortion services. Beyond the Numbers: 
Access to Reproductive Health Care for Low-Income Women in Five Communities, KAISER 
FAM. FOUND. (Nov. 14, 2019), https://www.kff.org/womens-health-policy/report/beyond-the-
numbers-access-to-reproductive-health-care-for-low-income-women-in-five-communities/ 
[hereinafter KAISER, Beyond the Numbers]. 
 126 KAISER, Coverage, supra note 124. 
 127 Nicole E. Johns, Diana Greene Foster & Ushma D. Upadhyay, Distance traveled for 
Medicaid-covered abortion care in California, 17 BMC HEALTH SERV. RES. 287 (2017) (citing 
CALIF. DEP’T OF HEALTH CARE SERVS., Medi-Cal funded induced abortions, 2010). 
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miles to obtain a publicly funded abortion.128,129  
 A Kaiser Family Foundation case study of Tulare County, located in the 
central region, illustrates the issue of access.130  One of the poorest counties 
in California, Tulare has a host of challenges present in regions across the 
State: extreme poverty, prevalence of domestic violence, and a significant 
population of undocumented immigrants who face language barriers and/or 
do not seek services out of fear of deportation.131  Women in Tulare County 
cited transportation, cost, stigma, and “fear of family members finding out” 
as major hurdles to accessing abortion.132  Those who do seek abortion care 
must travel more than fifty miles to the nearest city of Fresno.133  Study 
participants said that the community is conservative largely due to Roman 
Catholic influence in the sixty-five percent Hispanic population, which leads 
to resistance to abortion from both providers and patients.134  Considering 
Tulare, it is no surprise that patients who rely on Medi-Cal across the State 
have difficulty finding a provider where they live.   
 Further, misconceptions and misinformation about Medi-Cal eligibility 
also affect enrollment in the Medi-Cal program.135  According to data and 
anecdotal evidence, patients are sometimes incorrectly told that they need to 
submit certain forms or information, such as citizenship documents, in order 
to qualify for coverage.136  (In reality, citizenship documents are not 
required.137)  Again, these misconceptions lead to delayed care, pregnancy-
related complications, and carrying unwanted pregnancies to term.138  
 Finally, California’s low Medi-Cal reimbursement rates are an obstacle 
to MAB access.  In a multi-state study of barriers to Medicaid acceptance for 
all methods of abortion, providers cited low reimbursement rates as the 
 
 128 Rachel K. Jones, Elizabeth Witwer & Jenna Jerman, Abortion Incidence and Service 
Availability in the United States, 2017, GUTTMACHER INST. (Sept. 2019), 
https://www.guttmacher.org/report/abortion-incidence-service-availability-us-2017. 
 129 Nicole E. Johns, Diana Greene Foster & Ushma D. Upadhyay, Distance traveled for 
Medicaid-covered abortion care in California, 17 BMC HEALTH SERV. RES. 287 (2017). 
 130 KAISER, Beyond the Numbers, supra note 125. 
 131 Id. 
 132 Id. 
 133 Id. 
 134 Id.  
 135 Barriers to abortion care in California: Highlighting challenges of Medi-Cal 




 136 Id. 
 137 Id. 
 138 Id. 
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primary barrier.139  While reimbursement rates and costs of services vary, 
California has one of the lowest average Medicaid reimbursement rates for 
physicians in the country.140  This was exacerbated in 2015 with the passage 
of AB 97, which enacted a ten percent reduction in reimbursement rates for 
most fee-for-service Medi-Cal providers.141  Low reimbursement rates for 
abortion services can result in steep out-of-pocket costs for patients; fewer 
providers who accept federal insurance coverage due to lack of 
reimbursement or process hassles that outweigh the benefits of receiving such 
low payments; and, clinic closures or reductions in staff due to significant 
losses on un-reimbursed services.142  
 When seeking Medi-Cal reimbursement specifically for MAB, providers 
receive a bundled payment for services rendered over a fourteen-to-eighteen-
day period and include all office visits, pelvic ultrasounds, laboratory studies, 
urine pregnancy tests, and patient counseling.143  One of the costliest pieces 
of the bundled payment requirements is the pelvic ultrasound.  To be eligible 
for reimbursement, MAB patients in California are required to receive two 
in-office ultrasounds: the first to determine gestational age of the pregnancy 
before MAB, and the second, performed after the pill regimen, to ensure 
termination is complete.144  The cost of a pregnancy ultrasound typically 
ranges from $200 to $300 but can be significantly more (the Healthcare 
Bluebook estimates a “fair” price at $225, though this does not correspond to 
reimbursement rates for ultrasounds in the in the  Medi-Cal fee schedule).145  
According to data from DHCS, in 2014 the average reimbursement rate for 
fee-for-service, Medi-Cal-funded MAB provision service was $561.146  Thus, 
 
 139 Amanda Dennis & Kelly Blanchard, Abortion Providers’ Experiences with Medicaid 
Abortion Coverage Policies: A Qualitative Multistate Study, 48 HEALTH SERV. RES. 1, 236-52 
(2013). 
 140 HHS Administrative Complaint: Inadequate Access to Health Care Violates Latino 
Civil Rights in California’s Medi-Cal Program, NAT’L HEALTH LAW PROGRAM (Dec. 15, 
2015), https://healthlaw.org/resource/hhs-administrative-complaint-inadequate-access-to-
health-care-violates-latino-civil-rights/. 
 141 Assembly Bill 97 Ten Percent Pharmacy Payment Reductions, CALIF. DEP’T OF 
HEALTH CARE SERVS., 
https://www.dhcs.ca.gov/provgovpart/pharmacy/Pages/AB97Main.aspx (last modified Sept. 
10, 2019, 2:41 PM). 
 142 Dennis & Blanchard, supra note 139. 
 143 Medi-Cal Provider Manual, supra note 33. 
 144 Id. 
 145 Ruthie Dean, Expecting? How Much Does an Ultrasound Cost?, BERNARD BENEFITS 
(Oct. 14, 2020), https://blog.bernardbenefits.com/expecting-how-much-does-an-ultrasound-
cost. 
 146 Reimbursement for early pregnancy surgical abortions in 2014 averaged $438. This 
price differential can be attributed to the costs of pills and to the two-ultrasound requirement 
for MAB. CALIF. DEP’T OF HEALTH CARE SERVS., RSCH. & ANALYTIC STUDIES DIV., Medi-Cal-
Funded Induced Abortions, 2014 (Oct. 2016), 
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after covering costs of the ultrasounds, that leaves just a little over $100 to 
cover the cost of pills, pregnancy and lab tests, plus all remaining staff, office, 
and administrative costs.  
 Additionally, it is not uncommon for MAB patients to skip the follow-up 
appointment and the second ultrasound for logistical or personal reasons, 
including the inability to take off work, lack of childcare, and the emotional 
stress of returning to a clinic.147  In these instances, which are uniquely out 
of providers’ control, providers must use a modifier on their billing that drops 
reimbursement down by almost fifty percent—a sizable decrease in 
reimbursement despite the fact that all other costs of provision remain the 
same.148  Thus, for many safety-net providers who primarily serve low-
income patients, the significant decrease in the reimbursement rate brought 
about by the modifier makes it is financially difficult to accept Medi-Cal 
insurance for MAB. 
 
C. Recommendation: California Should Eliminate Pelvic 
Ultrasounds from MAB Medi-Cal Reimbursement 
Requirements 
 
 Following the July 2020 federal injunction on the FDA REMS for 
mifepristone, DHCS issued a directive temporarily relaxing requirements for 
MAB reimbursement under Medi-Cal.149  DHCS lifted both enforcement of 
the FDA’s in-person requirements and the ultrasound requirement from the  
bundled payment option coded as S0191:  
 
Providers who bill using HCPCS code S0191 to prescribe 
mifepristone to end early pregnancies, may provide 
medically necessary services without an in-person visit or 
signature … Further, DHCS is revising the Abortion (abort) 
section of the Provider Manual to ensure flexibilities exist for 
providing medically necessary abortion services during the 
COVID-19 public health emergency and to remove 






 147 Matsubara, supra note 96. 
 148 Id. 
 149 Important News about Women’s Health Services, CALIF. DEP’T OF HEALTH CARE 
SERVS. (July 29, 2020), https://files.medi-
cal.ca.gov/pubsdoco/newsroom/newsroom_30339_77.aspx. 
 150 Id. (emphases added). 
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 Permanently eliminating the requirements for ultrasounds for Medi-Cal 
reimbursement, and rather allowing providers the flexibilities to provide 
appropriate MAB care based on patient needs and desires, would be a huge 
win for providers and patients. Not only is the dual ultrasound requirement 
costly, but it is not medically necessary for patient safety and procedural 
efficacy.151  
 The three primary goals of a clinical evaluation before MAB are to 
confirm that the gestational age is within accepted limits for safe and 
effective outpatient treatment, to identify ectopic pregnancy, and to establish 
that the patient has no contraindications to mifepristone or misoprostol.152  
Historically, an ultrasound is used during clinical evaluation because it was 
thought to be the best way to determine gestational age of a pregnancy—but 
it is not the only way to do so: as previously discussed, a no-touch protocol 
utilizing patient-reported information about last menstrual period (LMP) can 
help clinicians date gestational age of a pregnancy to an extremely high 
degree of accuracy.153  In fact, a prospective study conducted in 2015-2016 
in the United States, Mexico, and Moldova provided 406 medication 
abortions without ultrasound or pelvic examination, and no reported serious 
adverse events were connected to these omissions.154  The National Abortion 
Federation’s clinical policy guidelines state that “the use of ultrasound is not 
a requirement for the provision of first-trimester abortion care”; rather, “use 
of ultrasound may inform clinical decision-making.”155  The FDA does not 
require ultrasounds as part of the REMS for mifepristone.  In fact, the 
Medication Guide for Mifeprex does not require an ultrasound but says that 
a provider “may do a clinical examination, an ultrasound examination, or 
other testing to determine how far along [the patient is] in pregnancy.”156  
 The second primary goal of the traditional clinical evaluation before 
MAB is to identify ectopic pregnancy, a serious condition that occurs when 
a fertilized egg attaches itself not to the uterus but to a fallopian tube, 
abdominal cavity, or cervix.157  Similar to LMP dating, ectopic pregnancies 
 
 151 Raymond et al., supra note 72. 
 152 Id. 
 153 Hillary Bracken et al., Alternatives to routine ultrasound for eligibility assessment 
prior to early termination of pregnancy with mifepristone–misoprostol., 118 BJOG 17, 17-23 
(2011). 
 154 For more than 15 years, international organizations have provided tens of thousands 
of patients with MAB medications by mail, after screening them only by history. Raymond et 
al., supra note 72. 
 155 2020 Clinical Policy Guidelines for Abortion Care, NAT’L ABORTION FED’N, 
https://5aa1b2xfmfh2e2mk03kk8rsx-wpengine.netdna-ssl.com/wp-
content/uploads/2020_CPGs.pdf (last visited Feb. 28, 2021) (emphasis added). 
 156 Medication Guide: Mifeprex, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/media/72923/download (last visited Feb. 28, 2021). 
 157 Raymond et al., supra note 72. 
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can be identified through patient-reported information regarding recent 
vaginal bleeding, pelvic pain or cramping, medical history of pelvic 
inflammatory disease, or presence of an intrauterine device at conception.158  
While it must be noted that many patients with ectopic pregnancies will 
exhibit no risk factors, data suggests that the incidence of ectopic pregnancy 
among patients seeking MAB is less than one percent.159  Further, the 
condition can be determined post-MAB through other means like take-home 
pregnancy testing.160  
 In terms of the third goal of identifying contraindications to the 
medication, clinicians can use specific questions about medical history and 
symptoms, typical of routine medication screening, to determine whether a 
patient is at risk before prescribing.161  
 The follow-up ultrasound requirement after MAB is similarly medically 
unnecessary.  The primary goals of the follow-up are to confirm termination 
of pregnancy, to detect ectopic pregnancies that were previously 
undiagnosed, and to identify any complications in need of treatment.162  
Patient-reported information about symptoms can be used in conjunction 
with high-sensitivity pregnancy tests to accomplish these goals, bypassing 
the need for an ultrasound.163  (For example, a pregnancy test showing 
positive post-MAB could suggest presence of an ectopic pregnancy.)  
Moreover, as previously mentioned, patients are often “lost to follow-up,” 
i.e. they do not present in-office after completing the pill regimen.164  
ACOG’s most recent guidelines state that routine in-person follow-ups with 
an ultrasound are not necessary after an uncomplicated medication 
abortion.165  Some clinicians have even offered patients the option to conduct 
a follow-up appointment by telephone or video as a more convenient and less 
emotionally taxing alternative to presenting in-office.166   
 A relaxation of the ultrasound requirement could catalyze a domino 
effect of positive change. Once data from California MAB providers using 
no-touch protocols is analyzed, it will likely underscore the conclusion that 
 
 158 Raymond et al., supra note 72. 
 159 Id. 
 160 Id. 
 161 Id. 
 162 Id. 
 163 Id. 
 164 See, e.g., Medication Abortion Up to 70 Days Gestation, ACOG Practice Bulletin 
(Oct. 2020), https://www.acog.org/-/media/project/acog/acogorg/clinical/files/practice-
bulletin/articles/2020/10/medication-abortion-up-to-70-days-gestation.pdf. 
 165  Id. 
 166 A study found that offering alternative follow-up options to in-person visits, such as 
telephone or video conferences, may decrease the proportion of women who are lost to follow-
ups. Melissa J. Chen et al., Comparing office and telephone follow-up after medical abortion, 
94 CONTRACEPTION 122, 122-26 (2016). 
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ultrasounds are not necessary to ensure safe and effective MAB provision.  
This could reinforce the case for permanent elimination of the ultrasound 
requirements for Medi-Cal reimbursement, leading to higher reimbursements 
for MAB, an increase in the number and geographic distribution of providers 
accepting Medi-Cal for MAB, and broadened access for Californians who 
need it most—those who rely on Medi-Cal and those who live in areas far 
from clinics and hospitals. 
 
IV. TELEHEALTH MEDICATION ABORTION AND 
MINOR CONSENT 
 
 As telehealth for MAB becomes more viable, a specific patient 
population is currently being overlooked in California: minors.  Minors in 
California do not need parental involvement to access MAB, but they may 
not be able to receive telehealth services without parental consent.167  This 
statutory mismatch creates a paradox wherein a minor can consent to a 
treatment, but not to the modality of its prescription.  Because telehealth 
consent requirements have been temporarily suspended in California under 
Executive Order by the governor, this is unlikely to become an urgent issue 
for the duration of the COVID-19 public health emergency.168  However, this 
loophole may effectively prevent some minors from accessing MAB via 
telehealth in the future.  As the State looks ahead to a future with fewer 
restrictions on MAB, it is critical to address this issue. 
 
A. The Minor-TeleMAB Paradox 
 
 Under section 123450 of the California Health and Safety Code, minors 
may not obtain abortion care without parental consent.169  But in the 1997 
case of American Academy of Pediatrics v. Lungren, the California Supreme 
Court found this statute in violation of the California Constitution.170  The 
court held that a parental consent statute “impinges upon a fundamental 
autonomy privacy interest” and “denies a pregnant minor, who believes it is 
in her best interest to terminate her pregnancy rather than have a child at such 
a young age, control over her own destiny.”171  The court reasoned that the 
statute most significantly impacted pregnant minors who were “too 
frightened or too embarrassed to disclose her condition to a parent (or to a 
 
 167 Am. Acad. of Pediatrics v. Lungren, 940 P.2d 797 (Cal. 1997). 
 168 Calif. Exec. Order No. N-43-20 (Apr. 3, 2020), https://www.gov.ca.gov/wp-
content/uploads/2020/04/4.3.20-EO- N-43-20-text.pdf. 
 169 CAL. HEALTH & SAFETY CODE § 123450. 
 170 Am. Acad. of Pediatrics v. Lungren, 940 P.2d 797 (Cal. 1997). 
 171 Id. at 338-39. 
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court).”172 Unlike thirty-seven other states, California does not require 
parental involvement or judicial authorization for a minor to obtain an 
abortion.173 
 Because California does not restrict provision of MAB via telehealth, 
logic dictates that a pregnant minor should be able to legally access TeleMAB 
services.174  However, the U.S. Constitution protects the right of parents to 
consent to the medical treatment of their children.175  A violation of that right 
has been found relevant under both the Fourth Amendment and the due 
process clause of the Fourteenth Amendment.176  While the U.S. Supreme 
Court has not defined the exact scope of a parent’s right to direct their child’s 
medical care, the Court has consistently acknowledged—and upheld—the 
existence of that parental right.177  In California, a minor may not consent to 
medical care unless the minor is fifteen years old, lives “separate and apart” 
from parents or guardians, and manages their own finances.178   
 Today, the State permits the use of telehealth for most service provision 
as long as it is performed by a California licensed physician and complies 
with state and federal privacy laws.179  Under section 2290.5 of the Business 
and Professions Code, a patient must give verbal or written consent to 
telehealth as a modality of care.180  However, unlike the State’s laws allowing 
minors to consent to certain sensitive services like abortion as mentioned 
above,  no language exempts the telehealth consent requirement for minors 
seeking virtual care.  Therefore, minors seeking telehealth services for MAB 
likely still require parental consent.181   
 
 
 172 Lungren, 940 P.2d at 314. 
 173 Parental Involvement in Minors’ Abortions, GUTTMACHER INST., 
https://www.guttmacher.org/state-policy/explore/parental-involvement-minors-abortions 
(last visited Feb. 28, 2021). 
 174 See, e.g., Jeltsen, supra note 65 (discussing the solution telemedicine can provide). 
 175 Troxel v. Granville, 530 U.S. 57, 66 (2000). 
 176 Dubbs v. Head Start, Inc., 336 F.3d 1194, 1222 (10th Cir. 2003). 
 177 Emily G. Narum, Making the Grade: School-Based Telemedicine and Parental 
Consent, 53 SAN DIEGO L. REV. 745, 753 (2016). 
 178  CAL. FAM. CODE § 6922. 
 179 Practicing Medicine Through Telehealth Technology, MED. BD. OF CAL., 
https://www.mbc.ca.gov/Licensees/Telehealth.aspx (last visited Feb. 28, 2021).  
 180 CAL. BUS. & PROF. CODE § 2290.5. (“Before the delivery of health care via telehealth, 
the health care provider initiating the use of telehealth shall inform the patient about the use 
of telehealth and obtain verbal or written consent from the patient for the use of telehealth as 
an acceptable mode of delivering health care services and public health. The consent shall be 
documented.”). 
 181 For an example of written confirmation of parental consent to telehealth for their 
minor child, see this form from Bay Area Clinical Associates: 
https://static1.squarespace.com/static/54650b6ee4b0788b699fe06a/t/5e70e5286a26061dbb4
06a3d/1584457001997/Telehealth+Consent+-+Minor+%28COVID-19%29.pdf.  
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B. Recommendation: California Should Close the Loophole and 
Permit Minor Consent to Telehealth Services for MAB 
 
 It is easy to see how this dissonance may be the result of simple oversight, 
but it is one that should be corrected.  Minors are a unique patient population 
in that they tend to lack autonomy and control over their life situations and 
are therefore particularly susceptible to delays in abortion care—especially 
those who do not live near a clinic or hospital, do not have money or means 
of travel, or are too frightened to tell their parents.  Thus, it is especially 
important that State policies do not obstruct minors from accessing safe, legal 
abortion care in addition to other services that they can legally consent to 
without parental involvement.  California can ensure minors’ rights to obtain 
an abortion by allowing minors to consent to telehealth provision of MAB 
without parental consent.  A solution should ensure that the State’s telehealth 
consent requirements align with existing laws that allow minors to consent 
to certain health care services.  
 This clarification could take the form of an amendment to State telehealth 
policy, which is dictated by the Telemedicine Development Act of 1996, the 
Telehealth Advancement Act of 2011, and several subsequent statutes 
enacted by the legislature.182  Such an amendment would have substantial 
grounding in the Lungren case, which specifically gives credence to 
aforementioned concerns about privacy, safety, and infringement on personal 
autonomy.183  The State should act to mitigate this complication before the 
end of the public health emergency, at which time mandatory consent for 
telehealth will be reinstated. 
 A counterargument to closing this loophole would be a slippery slope 
concern: if minors can provide their own consent for telehealth services, then 
soon enough parents will be completely bypassed in decisions about their 
children’s medical care.  This argument is a fallacy.  No compelling evidence 
suggests that Lungren has led to significantly less parental involvement in 
their children’s medical care; therefore, there is no reason to expect that the 
case would be different for telehealth for MAB.  Minors should be able to 
access services they can legally consent to without parental involvement—






 182 CAL. BUS. & PROF. CODE § 2060; California Policy: Telehealth Advancement Act, CTR. 
FOR CONNECTED HEALTH POL’Y, https://www.cchpca.org/telehealth-policy/telehealth-
advancement-act (last visited Feb. 28, 2021). 
 183 Lungren, 940 P.2d at 800. 
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V. CONCLUSION 
 
 “As goes California, so goes the nation.”184  Californians take pride in 
pioneering and influencing innovative policy on a range of issues, from 
environmental conservation to cutting-edge technology.  While it is true that 
California is at the forefront of progress in reproductive rights, there is much 
more we can do to expand access to Californians—and to continue to push 
the rest of the country forward. 
 Medication abortion is safe, effective, and, as evidenced by current 
conditions, has unique power to reach low-income and rural patients.  By 
supporting the collection of no-touch and TeleMAB data during the COVID-
19 public health emergency, revisiting the ultrasound requirements for Medi-
Cal reimbursement, and closing the loophole preventing minors from 
accessing TeleMAB, California can lean into its role as a reproductive 
freedom state.  These are feasible solutions that align with the State’s 
commitment to reproductive justice for all. 
 
 184 This common political maxim, here referring to California policy innovation, can be 
traced to the state of Maine, which once served as a bellwether for U.S. presidential elections.  
Andrew Glass, ‘As Maine goes, so goes the nation,’ Sept. 8, 1958, POLITICO (Sept. 8, 2016), 
https://www.politico.com/story/2016/09/as-maine-goes-so-goes-the-nation-sept-8-1958-
227727.  
